The road to an investigational new drug (IND) application can be long, complex and costly.
At Quotient Sciences we have proven that we know what it takes to develop a successful drug candidate—through early development and beyond. We can help as you're looking to evaluate your product for further development and get ready for IND.
Our experienced team, global resources, and scientific expertise allow us to provide a comprehensive assessment of your molecule's developability. We collaborate with you to identify the best drug candidates and mitigate associated risks.
Navigate to IND with the help of Quotient Sciences.
One of the main challenges as you prepare for IND is the requirement for extensive documentation. The FDA requires a range of documentation including chemistry, manufacturing and control (CMC), pharmacology, and toxicology data.
As an integrated CDMO and CRO provider with more than 30 years of experience working on small molecule and peptide drug development programs, we can help your path forward. Here are some of the ways we can help:
- Drug Substance Synthesis: A streamlined approach to developing drug substance that can help reduce drug substance manufacturing costs by 50% from preclinical to Phase I. Explore drug substance capabilities >
- Preclinical Technology Screening: Even before entering clinical evaluation stages, new therapeutics must overcome higher solubility hurdles. Learn about our new service >
- Formulation Development: A range of services that can help you consider your ideal drug product formulation and help you get ready for first-in-human clinical testing. Learn about formulation development >
